These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12396792)

  • 1. Improving efficiency of ALS clinical trials: a sponsor's perspective.
    Markabi S; Schadrack J
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002; 3 Suppl 1():S7-8. PubMed ID: 12396792
    [No Abstract]   [Full Text] [Related]  

  • 2. A placebo arm is not always necessary in clinical trials of amyotrophic lateral sclerosis.
    Gordon PH
    Muscle Nerve; 2009 Jun; 39(6):858-60. PubMed ID: 19382169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving efficiency of ALS clinical trials using lead-in designs.
    Moore DH; Miller RG
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():57-60. PubMed ID: 15512875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The biopharmaceutical industry and new drugs for amyotrophic lateral sclerosis.
    Malta E
    Adv Neurol; 1995; 68():263-9; discussion 271-5. PubMed ID: 8787239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing clinical trials in amyotrophic lateral sclerosis.
    Shefner JM
    Phys Med Rehabil Clin N Am; 2008 Aug; 19(3):495-508, ix. PubMed ID: 18625412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic trials in ALS.
    Bradley W
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Apr; 4(1):6-7. PubMed ID: 12745610
    [No Abstract]   [Full Text] [Related]  

  • 7. ALS trial design: expectation and reality.
    Miller RG; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():52-4. PubMed ID: 15512873
    [No Abstract]   [Full Text] [Related]  

  • 8. ALS issues in clinical trials. Statistical issues.
    Levin B
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():43-5. PubMed ID: 15512870
    [No Abstract]   [Full Text] [Related]  

  • 9. What is next in ALS clinical trials?
    Sorenson EJ
    Neurology; 2007 Aug; 69(8):719-20. PubMed ID: 17709702
    [No Abstract]   [Full Text] [Related]  

  • 10. ALS combination treatment. Drug cocktails.
    Rosenfeld J
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():115-7. PubMed ID: 15512890
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug therapy for amyotrophic lateral sclerosis: Where are we now?
    Carter GT; Krivickas LS; Weydt P; Weiss MD; Miller RG
    IDrugs; 2003 Feb; 6(2):147-53. PubMed ID: 12789618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scrutinizing enrollment in ALS clinical trials: room for improvement?
    Bedlack RS; Pastula DM; Welsh E; Pulley D; Cudkowicz ME
    Amyotroph Lateral Scler; 2008 Oct; 9(5):257-65. PubMed ID: 18608092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selecting promising ALS therapies in clinical trials.
    Cheung YK; Gordon PH; Levin B
    Neurology; 2006 Nov; 67(10):1748-51. PubMed ID: 17130405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient orientated research and clinical trials.
    Bradley WG
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():137-40. PubMed ID: 15512898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An efficient multi-stage, single-arm Phase II futility design for ALS.
    Palesch YY; Tilley BC
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():55-6. PubMed ID: 15512874
    [No Abstract]   [Full Text] [Related]  

  • 16. Regulatory issues in ALS clinical trials.
    Bryan WW
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():36-41. PubMed ID: 15512868
    [No Abstract]   [Full Text] [Related]  

  • 17. Endpoint considerations for clinical trials.
    Walton MK
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002; 3 Suppl 1():S3-6. PubMed ID: 12396791
    [No Abstract]   [Full Text] [Related]  

  • 18. ALS issues in clinical trials. Missing data.
    Thompson JL; Levy G
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():48-51. PubMed ID: 15512872
    [No Abstract]   [Full Text] [Related]  

  • 19. Randomized control trials in ALS: lessons learned.
    Mitsumoto H; Gordon P; Kaufmann P; Gooch CL; Przedborski S; Rowland LP
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():8-13. PubMed ID: 15512861
    [No Abstract]   [Full Text] [Related]  

  • 20. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.